French pharma giant Sanofi said that international Phase 3 clinical tests of its Kevzara drug for serious Covid-19 cases had proved inconclusive and it was halting the trial.
The Phase 3 test - normally the last before official approval for use - "did not meet the primary or secondary evaluation criteria compared with a placebo, and in both cases, compared with established hospital care," it said in a statement.
Sanofi said neither it nor its American partner in developing the drug, Regeneron, "envisage further clinical tests of Kevzara for the treatment of Covid-19." Although Kevzara "did not give us the results we were hoping for, we are proud of the work done by our team," Sanofi global research head D.